The pill, S-217622, ”demonstrated rapid clearance of infectious SARS-CoV-2 virus,” Shionogi said in a statement, citing Phase 2b results from the drug’s Phase II/III clinical trial. .
The company has global aspirations for the antiviral pill, which is currently being evaluated by Japanese regulators.
Results released on Sunday also showed “there was no significant difference in the total score of 12 Covid-19 symptoms between the treatment arms”, although the drug showed improvement in a composite score. of five “respiratory and feverish” symptoms, Shionogi said.
The drugmaker said in March it would launch a worldwide Phase III trial for the drug with US government support, and chief executive Isao Teshirogi said production could reach 10 million doses per month. year.
Shionogi’s shares have been on a rollercoaster ride over speculation about the treatment’s success. The stock climbed on Friday after a report that the US government is in talks to source the drug.
On April 13, the stock fell 16% on reports that the drug may pose risks to pregnancies, based on preclinical data.